Sakar Healthcare Limited (NSEI: SAKAR)
Health Care · Pharmaceuticals · IN
Rs912.60
+4.18% today · +173.4% 1Y
Sakar Healthcare Limited (NSEI: SAKAR) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $212.22M and employs 325 people.
Over the last twelve months the share price has gained 173.4%, trading between 321.05 and 980.00.
Tweenvest scores Sakar Healthcare Limited across four factors: quality 75/100, value 21/100, growth 93/100. Its strongest factor is growth.
SAKAR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $212.22M
- Revenue (TTM)
- $28.76M
- P/E
- 56.33
- EPS
- 16.20
- Dividend yield
- —
- Beta (5Y)
- 0.45
- 52-week high
- Rs980.00
- 52-week low
- Rs321.05
- Avg volume (3M)
- —
- Shares outstanding
- 22.25M
- Employees
- 325
- Next earnings
- —
About Sakar Healthcare Limited
Sakar Healthcare Limited, founded in 2004 and based in Ahmedabad, India, is a pharmaceutical company actively involved in the full spectrum of drug development, from research and manufacturing to marketing its products. The company's diverse product line includes liquid oral medications, cephalosporin-based drugs (available as tablets, capsules, and dry powder syrups), various injectable forms such as dry powder injections, and liquid injectable solutions (supplied in ampoules, vials, and lyophilized preparations), alongside oral solid dosages. Their comprehensive portfolio addresses approximately 22 distinct therapeutic categories, encompassing treatments for conditions like acidity, malaria, blood clotting, constipation, respiratory issues, pain, infections, depression, allergies, and nutritional deficiencies, among others. Sakar Healthcare also has a significant global reach, distributing its products to roughly 38 countries across regions including Southeast Asia, other parts of Asia, both English and French-speaking African nations, the Middle East and North Africa, and the United States.
- ISIN
- INE732S01012
- Founded
- 2004
- Listed since
- Mar 16, 2017
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.06T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $650.67B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $377.72B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $365.10B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $300.07B | CHF127.18 | -0.90% |
| AstraZeneca PLCLSE: AZN | $257.89B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $210.23B | Dkr304.95 | -0.93% |
| Pfizer Inc.NYSE: PFE | $161.30B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.